This FDA approval is a transformative catalyst for BFRI, opening a large new market for its existing PDT platform with minimal incremental cost. Traders should watch for early adoption metrics and any analyst upgrades following the launch in late Q4 2026 through Q1 2027, as well as potential for increased RhodoLED lamp sales to new dermatology practices.
Price Chart
Executive Summary
Biofrontera announced FDA approval of its supplemental New Drug Application for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED lamp series, for the treatment of superficial basal cell carcinoma (sBCC) in adults. This makes Ameluz the first and only photodynamic therapy approved in the U.S. to treat a skin cancer, expanding its addressable market from actinic keratosis to a skin cancer indication with an estimated 540,000 to 720,000 annual U.S. cases. The company plans to launch the sBCC indication late in Q4 2026 through Q1 2027 using its existing commercial infrastructure, representing a significant growth catalyst for the company's PDT platform.
Key Facts
- FDA approved Biofrontera's sNDA for Ameluz PDT to treat superficial basal cell carcinoma (sBCC) in adults.
- Ameluz is now the first and only FDA-approved photodynamic therapy for a skin cancer in the U.S.
- The sBCC indication expands the addressable market to an estimated 540,000 to 720,000 annual U.S. cases.
- Phase 3 trial showed 66% of Ameluz PDT patients achieved the primary composite endpoint vs. 5% for placebo.
- Company plans to launch the sBCC indication late Q4 2026 through Q1 2027 with existing commercial team and lamp base.
Financial Impact
Expands addressable market from actinic keratosis to an estimated 540,000-720,000 annual sBCC cases in the U.S., creating a new revenue stream with no additional R&D investment required.
Risk Factors
- Commercial launch is not expected until late Q4 2026 through Q1 2027, creating a gap before revenue materializes.
- Reimbursement and market adoption by dermatologists for the new indication remain unproven.
- Company's financial position and ability to fund the commercial launch without additional dilutive financing is not disclosed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-042508 |
| Exhibit: ex99-1.htm | 0001493152-26-042508 |
| Document: 0001493152-26-042508-index-headers.html | 0001493152-26-042508 |
| Document: 0001493152-26-042508-index.html | 0001493152-26-042508 |
| Document: 0001493152-26-042508.txt | 0001493152-26-042508 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 8-K | $1.36 | awaiting T+60 | — | $0.8400 (−38.24%) |
Aug 13, 2026 10w ago | 8-K | $1.26 | awaiting T+60 | — | $0.8400 (−33.33%) |
May 14, 2026 23w ago | Press Release | $0.9890 $1.21 | ▲ +22.35% | ▲ +18.76% | $0.8400 (−15.07%) |
May 8, 2026 24w ago | Press Release | $1.11 $1.24 | ▲ +11.71% | ▲ +7.32% | $0.8400 (−24.32%) |
Mar 19, 2026 31w ago | Press Release | $0.8560 $1.00 | ▲ +16.82% | ▲ +2.48% | $0.8400 (−1.87%) |
Feb 26, 2026 34w ago | 8-K | $0.9270 $0.7790 | ▼ −15.97% | ▼ −23.72% | $0.8400 (−9.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers